Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 4, 2011, Pages 609-620

  Wu, Chung Pu ^a,b   Ohnuma, Shinobu ^a   Ambudkar, Suresh V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

ATP binding cassette transporters; Bioavailability; Chemotherapy; Modulators; Multidrug resistance; Natural products

Indexed keywords

3' 4' 7 TRIMETHOXYFLAVONE; 5 BROMOTETRANDRINE; 6 PRENYLCHRYSIN; ABC TRANSPORTER; ABIETANE DITERPENE; ACACETIN; AMOORANIN; BIOCHANIN A; BREAST CANCER RESISTANCE PROTEIN; CANNABINOID DERIVATIVE; CANTHARIDIN; CATECHIN; CEPHARANTHINE; CHRYSIN; COUMARIN DERIVATIVE; CURCUMIN; DAIZEIN; DEOXYSCHIZANDRIN; EUDESMIN; EUPATIN; FLAVONOID; GENISTEIN; GINKGO BILOBA EXTRACT; GINSENOSIDE; GLYCOPROTEIN P; HAPALOSIN; HARMINE; MULTIDRUG RESISTANCE PROTEIN 1; NATURAL PRODUCT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; HUMAN; MULTIDRUG RESISTANCE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; HUMANS; NEOPLASMS;

EID: 79953767571     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795163887     Document Type: Article

References (163)

1. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
2. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5(3), 219-234.
3. Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet., 2005, 6, 123-142.
4. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
5. Calcagno, A.M.; Kim, I.W.; Wu, C.P.; Shukla, S.; Ambudkar, S.V. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr. Drug Deliv., 2007, 4(4), 324-333.
6. Lagas, J.S.; Vlaming, M.L.; Schinkel, A.H. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol. Interv., 2009, 9(3), 136-145.
7. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86(4), 1179-1236.
8. Shukla, S.; Wu, C.P.; Ambudkar, S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Exp. Opin. Drug Metab. Toxicol., 2008, 4(2), 205-223.
9. Loe, D.W.; Deeley, R.G.; Cole, S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer, 1996, 32A(6), 945-957.
10. Szakacs, G.; Varadi, A.; Ozvegy-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today, 2008, 13(9-10), 379-393.
11. Chan, H.S.; Haddad, G.; Thorner, P.S.; DeBoer, G.; Lin, Y.P.; Ondrusek, N.; Yeger, H.; Ling, V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med., 1991, 325(23), 1608-1614.
12. Penson, R.T.; Oliva, E.; Skates, S.J.; Glyptis, T.; Fuller, A.F., Jr.; Goodman, A.; Seiden, M.V. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol., 2004, 93(1), 98-106.
13. Steinbach, D.; Sell, W.; Voigt, A.; Hermann, J.; Zintl, F.; Sauerbrey, A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia, 2002, 16(8), 1443-1447.
14. van den Heuvel-Eibrink, M.M.; Wiemer, E.A.; Prins, A.; Meijerink, J.P.; Vossebeld, P.J.; van der Holt, B.; Pieters, R.; Sonneveld, P. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia, 2002, 16(5), 833-839.
15. Hipfner, D.R.; Deeley, R.G.; Cole, S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta, 1999, 1461(2), 359-376.
16. Wu, C.P.; Calcagno, A.M.; Ambudkar, S.V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol., 2008, 1(2), 93-105.
17. Walker, J.; Martin, C.; Callaghan, R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur. J. Cancer, 2004, 40(4), 594-605.
18. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.; Booser, D.; Symmans, F.W.; Wong, F.; Blumenschein, G.; Fleming, D.R.; Rouzier, R.; Boniface, G.; Hortobagyi, G.N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104(4), 682-691.
19. Jekerle, V.; Wang, J.H.; Scollard, D.A.; Reilly, R.M.; Wiese, M.; Piquette-Miller, M. 99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides. Mol. Imaging Biol., 2006, 8(6), 333-339.
20. Polgar, O.; Bates, S.E. ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans., 2005, 33(Pt 1), 241-245.
21. Zhou, S.F.; Di, Y.M.; Chan, E.; Du, Y.M.; Chow, V.D.; Xue, C.C.; Lai, X.; Wang, J.C.; Li, C.G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab., 2008, 9(8), 738-784.
22. Ford, J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer, 1996, 32A(6), 991-1001.
23. Leonard, G.D.; Polgar, O.; Bates, S.E. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs, 2002, 3(11), 1652-1659.
24. Azzariti, A.; Porcelli, L.; Simone, G.M.; Quatrale, A.E.; Colabufo, N.A.; Berardi, F.; Perrone, R.; Zucchetti, M.; D'Incalci, M.; Xu, J.M.; Paradiso, A. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother. Pharmacol., 2009, 65(2), 335-346.
25. Shukla, S.; Sauna, Z.E.; Ambudkar, S.V. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrugresistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia, 2008, 22(2), 445-447.
26. Dai, C.L.; Tiwari, A.K.; Wu, C.P.; Su, X.D.; Wang, S.R.; Liu, D.G.; Ashby, C.R., Jr.; Huang, Y.; Robey, R.W.; Liang, Y.J.; Chen, L.M.; Shi, C.J.; Ambudkar, S.V.; Chen, Z.S.; Fu, L.W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res., 2008, 68(19), 7905-7914.
27. Stouch, T.R.; Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev., 2002, 54(3), 315-328.
28. Raub, T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm., 2006, 3(1), 3-25.
29. Rabindran, S.K.; Ross, D.D.; Doyle, L.A.; Yang, W.; Greenberger, L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res., 2000, 60(1), 47-50.
30. Allen, J.D.; van Loevezijn, A.; Lakhai, J.M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J.H.; Koomen, G.J.; Schinkel, A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther., 2002, 1(6), 417-425.
31. Chearwae, W.; Anuchapreeda, S.; Nandigama, K.; Ambudkar, S.V.; Limtrakul, P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem. Pharmacol., 2004, 68(10), 2043-2052.
32. Bisht, K.; Wagner, K.H.; Bulmer, A.C. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto-and DNA-protective dietary compounds. Toxicology, 2009, [Epub ahead of print; doi:10.1016/j.tox.2009.11.008].
33. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev., 2009, 14(2), 141-153.
34. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398.
35. De Clercq, E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med. Res. Rev., 2000, 20(5), 323-349.
36. Shishodia, S.; Singh, T.; Chaturvedi, M.M. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol., 2007, 595, 127-148.
37. Limtrakul, P.; Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell Biochem., 2007, 296(1-2), 85-95.
38. Chearwae, W.; Wu, C.P.; Chu, H.Y.; Lee, T.R.; Ambudkar, S.V.; Limtrakul, P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol., 2006, 57(3), 376-388.
39. Chearwae, W.; Shukla, S.; Limtrakul, P.; Ambudkar, S.V. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5(8), 1995-2006.
40. Shukla, S.; Zaher, H.; Hartz, A.; Bauer, B.; Ware, J.A.; Ambudkar, S.V. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm. Res., 2009, 26(2), 480-487.
41. Sharma, R.A.; Gescher, A.J.; Steward, W.P. Curcumin: the story so far. Eur. J. Cancer, 2005, 41(13), 1955-1968.
42. Singh, S. From exotic spice to modern drug? Cell, 2007, 130(5), 765-768.
43. Lao, C.D.; Ruffin, M.T.; Normolle, D.; Heath, D.D.; Murray, S.I.; Bailey, J.M.; Boggs, M.E.; Crowell, J.; Rock, C.L.; Brenner, D.E. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med., 2006, 6, 10.
44. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4(6), 807-818.
45. Li, L.; Braiteh, F.S.; Kurzrock, R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer, 2005, 104(6), 1322-1331.
46. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol., 2007, 5, 3.
47. Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 2009, 37(3-4), 223-230.
48. Mosley, C.A.; Liotta, D.C.; Snyder, J.P. Highly active anticancer curcumin analogues. Adv. Exp. Med. Biol., 2007, 595, 77-103.
49. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64(4), 353-356.
50. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4B), 2895-2900.
51. Grant, K.L.; Schneider, C.D. Turmeric. Am. J. Health Syst. Pharm., 2000, 57(12), 1121-1122.
52. Deodhar, S.D.; Sethi, R.; Srimal, R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res., 1980, 71, 632-634.
53. Lal, B.; Kapoor, A.K.; Asthana, O.P.; Agrawal, P.K.; Prasad, R.; Kumar, P.; Srimal, R.C. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res., 1999, 13(4), 318-322.
54. Hsu, C.H.; Cheng, A.L. Clinical studies with curcumin. Adv. Exp. Med. Biol., 2007, 595, 471-480.
55. Heng, M.C.; Song, M.K.; Harker, J.; Heng, M.K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol., 2000, 143(5), 937-949.
56. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14(14), 4491-4499.
57. Raj, N.K.; Sripal, R.M.; Chaluvadi, M.R.; Krishna, D.R. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian J. Pharmacol., 2001, 33(1), 2-16.
58. Patil, B.S.; Jayaprakasha, G.K.; Chidambara, M.K.N.; Vikram, A. Bioactive compounds: historical perspectives, opportunities, and challenges. J. Agric. Food Chem., 2009, 57(18), 8142-8160.
59. Crozier, A.; Jaganath, I.B.; Clifford, M.N. Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep., 2009, 26(8), 1001-1043.
60. Cushman, M.; Nagarathnam, D. Cytotoxicities of some flavonoid analogues. J. Nat. Prod., 1991, 54(6), 1656-1660.
61. Wang, H.K.; Xia, Y.; Yang, Z.Y.; Natschke, S.L.; Lee, K.H. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv. Exp. Med. Biol., 1998, 439, 191-225.
62. Choi, S. U.; Ryu, S. Y.; Yoon, S. K.; Jung, N. P.; Park, S. H.; Kim, K. H.; Choi, E. J.; Lee, C.O. Effects of flavonoids on the growth and cell cycle of cancer cells. Anticancer Res., 1999, 19(6B), 5229-5233.
63. Selway, J.W. Antiviral activity of flavones and flavans. Prog. Clin. Biol. Res., 1986, 213, 521-536.
64. Ferriola, P. C.; Cody, V.; Middleton, E. Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol., 1989, 38(10), 1617-1624.
65. Cushman, M.; Zhu, H.; Geahlen, R. L.; Kraker, A. J. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J. Med. Chem., 1994, 37(20), 3353-3362.
66. Cotelle, N.; Bernier, J. L.; Henichart, J. P.; Catteau, J. P.; Gaydou, E.; Wallet, J. C. Scavenger and antioxidant properties of ten synthetic flavones. Free Radic. Biol. Med., 1992, 13(3), 211-219.
67. Leslie, E. M.; Mao, Q.; Oleschuk, C. J.; Deeley, R. G.; Cole, S. P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol. Pharmacol., 2001, 59(5), 1171-1180.
68. Zhang, S.; Yang, X.; Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 2004, 65(5), 1208-1216.
69. Wu, C. P.; Calcagno, A. M.; Hladky, S. B.; Ambudkar, S.V.; Barrand, M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J., 2005, 272(18), 4725-4740.
70. Morris, M. E.; Zhang, S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci., 2006, 78(18), 2116-2130.
71. Cermak, R.; Wolffram, S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr. Drug Metab., 2006, 7(7), 729-744.
72. Brand, W.; Schutte, M. E.; Williamson, G.; van Zanden, J.J.; Cnubben, N.H.; Groten, J.P.; van Bladeren, P.J.; Rietjens, I. M. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed. Pharmacother., 2006, 60(9), 508-519.
73. Piao, Y.; Shin, S. C.; Choi, J. S. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm. Drug Dispos., 2008, 29(4), 245-249.
74. Forester, S. C.; Waterhouse, A. L. Metabolites are key to understanding health effects of wine polyphenolics. J. Nutr., 2009, 139(9), 1824S-1831S.
75. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with highaffinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev., 2002, 22(5), 512-529.
76. Bailey, D. G.; Spence, J. D.; Munoz, C.; Arnold, J. M. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337(8736), 268-269.
77. Zhang, S.; Morris, M. E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 2003, 304(3), 1258-1267.
78. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J. M.; Barron, D.; Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. USA, 1998, 95(17), 9831-9836.
79. Zhou, S.; Lim, L. Y.; Chowbay, B. Herbal modulation of Pglycoprotein. Drug Metab. Rev., 2004, 36(1), 57-104.
80. Dennis, T.; Fanous, M.; Mousa, S. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr. Cancer, 2009, 61(5), 587-597.
81. Bansal, T.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci., 2009, 12(1), 46-78.
82. Peng, S. X.; Ritchie, D. M.; Cousineau, M.; Danser, E.; Dewire, R.; Floden, J. Altered oral bioavailability and pharmacokinetics of Pglycoprotein substrates by coadministration of biochanin A. J. Pharm. Sci., 2006, 95(9), 1984-1993.
83. Choi, J. S.; Jo, B.W.; Kim, Y. C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm., 2004, 57(2), 313-318.
84. Choi, J. S.; Choi, H. K.; Shin, S. C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm., 2004, 275(1-2), 165-170.
85. Marchetti, S.; Mazzanti, R.; Beijnen, J. H.; Schellens, J. H. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist, 2007, 12(8), 927-941.
86. Ekhart, C.; Rodenhuis, S.; Smits, P. H.; Beijnen, J. H.; Huitema, A. D. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev., 2009, 35(1), 18-31.
87. Wu, L.; Xu, X.; Shen, J.; Xie, H.; Yu, S.; Liang, T.; Wang, W.; Shen, Y.; Zhang, M.; Zheng, S. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J. Surg. Oncol., 2007, 96(1), 62-68.
88. Jamroziak, K.; Mlynarski, W.; Balcerczak, E.; Mistygacz, M.; Trelinska, J.; Mirowski, M.; Bodalski, J.; Robak, T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol., 2004, 72(5), 314-321.
89. Wang, L.R.; Ishiguro, N.; Yamada, E.; Nishida, Y.; Sato, K.; Iwata, H. The effect of da-fang-feng-tang on treatment of type II collageninduced arthritis in DBA/1 mice. Am. J. Chin. Med., 1999, 27(2), 205-215.
90. Goto, H.; Shimada, Y.; Tanikawa, K.; Sato, S.; Hikiami, H.; Sekiya, N.; Terasawa, K. Clinical evaluation of the effect of daio (rhei rhizoma) on the progression of diabetic nephropathy with overt proteinuria. Am. J. Chin. Med., 2003, 31(2), 267-275.
91. Yokozawa, T.; Satoh, A.; Nakagawa, T.; Yamabe, N. Attenuating effects of wen-pi-tang treatment in rats with diabetic nephropathy. Am. J. Chin. Med., 2006, 34(2), 307-321.
92. Li, C. X.; Li, L.; Lou, J.; Yang, W. X.; Lei, T. W.; Li, Y. H.; Liu, J.; Cheng, M. L.; Huang, L. H. The protective effects of traditional Chinese medicine prescription, han-dan-gan-le, on CCl4-induced liver fibrosis in rats. Am. J. Chin. Med., 1998, 26(3-4), 325-332.
93. Schuppan, D.; Jia, J. D.; Brinkhaus, B.; Hahn, E. G. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology, 1999, 30(4), 1099-1104.
94. Stickel, F.; Schuppan, D. Herbal medicine in the treatment of liver diseases. Dig. Liver Dis., 2007, 39(4), 293-304.
95. Kuo, C. Successful treatment of complete left bundle branch block complicating acute viral myocarditis employing Chinese herbs. Am. J. Chin. Med., 1986, 14(3-4), 124-130.
96. Chen, X. J.; Bian, Z. P.; Lu, S.; Xu, J. D.; Gu, C. R.; Yang, D.; Zhang, J. N. Cardiac protective effect of Astragalus on viral myocarditis mice: comparison with Perindopril. Am. J. Chin. Med., 2006, 34(3), 493-502.
97. Katayama, K.; Masuyama, K.; Yoshioka, S.; Hasegawa, H.; Mitsuhashi, J.; Sugimoto, Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol., 2007, 60(6), 789-797.
98. Jin, J.; Wang, F. P.; Wei, H.; Liu, G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol., 2005, 55(2), 179-188.
99. Ahmed-Belkacem, A.; Pozza, A.; Munoz-Martinez, F.; Bates, S. E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Perez-Victoria, J. M. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res., 2005, 65(11), 4852-4860.
100. Madureira, A. M.; Molnar, A.; Abreu, P. M.; Molnar, J.; Ferreira, M. J. A new sesquiterpene-coumarin ether and a new abietane diterpene and their effects as inhibitors of P-glycoprotein. Planta Med., 2004, 70(9), 828-833.
101. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y. Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res., 2004, 64(12), 4346-4352.
102. Mitsuo, M.; Noguchi, T.; Nakajima, Y.; Aoki, S.; Ren, X. Q.; Sumizawa, T.; Haraguchi, M.; Kobayashi, M.; Baba, M.; Nagata, Y.; Akiyama, S.; Furukawa, T. Binding site(s) on P-glycoprotein for a newly synthesized photoaffinity analog of agosterol A. Oncol. Res., 2003, 14(1), 39-48.
103. Wang, C.; Zhang, J. X.; Shen, X. L.; Wan, C. K.; Tse, A. K.; Fong, W. F. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem. Pharmacol., 2004, 68(5), 843-855.
104. Ramachandran, C.; Rabi, T.; Fonseca, H. B.; Melnick, S. J.; Escalon, E. A. Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines. Int. J. Cancer, 2003, 105(6), 784-789.
105. Engi, H.; Hohmann, J.; Gang, G.; Pusztai, R.; Redei, D.; Kovacs, O.; Schelz, Z.; Molnar, J. Chemoprevention and inhibition of Pglycoprotein in cancer cells by Chinese medicinal herbs. Phytother. Res., 2008, 22(12), 1671-1676.
106. Lee, Y.; Yeo, H.; Liu, S.H.; Jiang, Z.; Savizky, R. M.; Austin, D. J.; Cheng, Y.C. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring. J. Med. Chem., 2004, 47(22), 5555-5566.
107. Limtrakul, P.; Khantamat, O.; Pintha, K. Inhibition of Pglycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother. Pharmacol., 2004, 54(6), 525-530.
108. Zheng, L. H.; Bao, Y. L.; Wu, Y.; Yu, C. L.; Meng, X.; Li, Y. X. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett., 2008, 272(1), 102-109.
109. Holland, M. L.; Allen, J. D.; Arnold, J.C. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol., 2008, 591(1-3), 128-131.
110. Zhu, H. J.; Wang, J. S.; Markowitz, J. S.; Donovan, J. L.; Gibson, B. B.; Gefroh, H. A.; Devane, C. L. Characterization of Pglycoprotein inhibition by major cannabinoids from marijuana. J. Pharmacol. Exp. Ther., 2006, 317(2), 850-857.
111. Holland, M. L.; Panetta, J. A.; Hoskins, J. M.; Bebawy, M.; Roufogalis, B. D.; Allen, J. D.; Arnold, J. C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol., 2006, 71(8), 1146-1154.
112. Holland, M. L.; Lau, D. T.; Allen, J. D.; Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol., 2007, 152(5), 815-824.
113. Kitagawa, S.; Nabekura, T.; Kamiyama, S. Inhibition of Pglycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 2004, 56(8), 1001-1005.
114. Koizumi, S.; Konishi, M.; Ichihara, T.; Wada, H.; Matsukawa, H.; Goi, K.; Mizutani, S. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123. Eur. J. Cancer, 1995, 31A(10), 1682-1688.
115. Abe, T.; Koike, K.; Ohga, T.; Kubo, T.; Wada, M.; Kohno, K.; Mori, T.; Hidaka, K.; Kuwano, M. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br. J. Cancer, 1995, 72(2), 418-423.
116. Raad, I.; Terreux, R.; Richomme, P.; Matera, E. L.; Dumontet, C.; Raynaud, J.; Guilet, D. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter Pglycoprotein. Bioorg. Med. Chem., 2006, 14(20), 6979-6987.
117. Anuchapreeda, S.; Leechanachai, P.; Smith, M. M.; Ambudkar, S. V.; Limtrakul, P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol., 2002, 64(4), 573-582.
118. Madureira, A. M.; Spengler, G.; Molnar, A.; Varga, A.; Molnar, J.; Abreu, P. M.; Ferreira, M. J. Effect of cycloartanes on reversal of multidrug resistance and apoptosis induction on mouse lymphoma cells. Anticancer Res., 2004, 24(2B), 859-864.
119. Cooray, H. C.; Janvilisri, T.; van Veen, H. W.; Hladky, S. B.; Barrand, M. A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317(1), 269-275.
120. Yoo, H. H.; Lee, M.; Lee, M. W.; Lim, S.Y.; Shin, J.; Kim, D. H. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med., 2007, 73(5), 444-450.
121. Lim, S.; Grassi, J.; Akhmedjanova, V.; Debiton, E.; Balansard, G.; Beliveau, R.; Barthomeuf, C. Reversal of P-glycoprotein-mediated drug efflux by eudesmin from Haplophyllum perforatum and cytotoxicity pattern versus diphyllin, podophyllotoxin and etoposide. Planta Med., 2007, 73(15), 1563-1567.
122. Henrich, C. J.; Bokesch, H. R.; Dean, M.; Bates, S. E.; Robey, R. W.; Goncharova, E.I.; Wilson, J.A.; McMahon, J.B. A highthroughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen., 2006, 11(2), 176-183.
123. Corea, G.; Fattorusso, E.; Lanzotti, V.; Motti, R.; Simon, P. N.; Dumontet, C.; Di Pietro, A. Structure-activity relationships for euphocharacins A-L, a new series of jatrophane diterpenes, as inhibitors of cancer cell P-glycoprotein. Planta Med., 2004, 70(7), 657-665.
124. Robey, R. W.; Medina-Perez, W.Y.; Nishiyama, K.; Lahusen, T.; Miyake, K.; Litman, T.; Senderowicz, A. M.; Ross, D. D.; Bates, S. E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 2001, 7(1), 145-152.
125. Nabekura, T.; Yamaki, T.; Ueno, K.; Kitagawa, S. Inhibition of Pglycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother. Pharmacol., 2008, 62(5), 867-873.
126. Fan, L.; Tao, G. Y.; Wang, G.; Chen, Y.; Zhang, W.; He, Y. J.; Li, Q.; Lei, H. P.; Jiang, F.; Hu, D. L.; Huang, Y. F.; Zhou, H. H. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother., 2009, 43(5), 944-949.
127. Kim, S. W.; Kwon, H. Y.; Chi, D. W.; Shim, J. H.; Park, J. D.; Lee, Y. H.; Pyo, S.; Rhee, D. K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol., 2003, 65(1), 75-82.
128. Jin, J.; Shahi, S.; Kang, H. K.; van Veen, H. W.; Fan, T. P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun., 2006, 345(4), 1308-1314.
129. de Castro, W. V.; Mertens-Talcott, S.; Derendorf, H.; Butterweck, V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci., 2007, 96(10), 2808-2817.
130. Palomo, C.; Oiarbide, M.; Garcia, J. M.; Gonzalez, A.; Pazos, R.; Odriozola, J. M.; Banuelos, P.; Tello, M.; Linden, A. A practical total synthesis of hapalosin, a 12-membered cyclic depsipeptide with multidrug resistance-reversing activity, by employing improved segment coupling and macrolactonization. J. Org. Chem., 2004, 69(12), 4126-4134.
131. Ma, Y.; Wink, M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother. Res., 2010, 24(1), 146-149.
132. Wang, E. J.; Barecki-Roach, M.; Johnson, W. W. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. J. Pharm. Pharmacol., 2004, 56(1), 123-128.
133. Wang, T. X.; Yang, X. H. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on Pglycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Yao Xue Xue Bao, 2008, 43(5), 461-466.
134. Hohmann, J.; Redei, D.; Forgo, P.; Molnar, J.; Dombi, G.; Zorig, T. Jatrophane diterpenoids from Euphorbia mongolica as modulators of the multidrug resistance of L5128 mouse lymphoma cells. J. Nat. Prod., 2003, 66(7), 976-979.
135. Patanasethanont, D.; Nagai, J.; Yumoto, R.; Murakami, T.; Sutthanut, K.; Sripanidkulchai, B. O.; Yenjai, C.; Takano, M. Effects of Kaempferia parviflora extracts and their flavone constituents on Pglycoprotein function. J. Pharm. Sci., 2007, 96(1), 223-233.
136. Patanasethanont, D.; Nagai, J.; Matsuura, C.; Fukui, K.; Sutthanut, K.; Sripanidkulchai, B. O.; Yumoto, R.; Takano, M. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur. J. Pharmacol., 2007, 566(1-3), 67-74.
137. Weiss, J.; Sauer, A.; Frank, A.; Unger, M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit Pglycoprotein in vitro. Drug Metab. Dispos., 2005, 33(11), 1580-1583.
138. Aoki, S.; Cao, L. W.; Matsui, K.; Rachmat, R.; Akiyama, S.; Kobayashi, M. Kendarimide A, a novel peptide reversing Pglycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp. Tetrahedron, 2004, 60(33), 7053-7059.
139. van Zanden, J. J.; de Mul, A.; Wortelboer, H. M.; Usta, M.; van Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol., 2005, 69(11), 1657-1665.
140. Soenen, D. R.; Hwang, I.; Hedrick, M. P.; Boger, D. L. Multidrug resistance reversal activity of key ningalin analogues. Bioorg. Med. Chem. Lett., 2003, 13(10), 1777-1781.
141. Tao, H.; Hwang, I.; Boger, D. L. Multidrug resistance reversal activity of permethyl ningalin B amide derivatives. Bioorg. Med. Chem. Lett., 2004, 14(24), 5979-5981.
142. Hemauer, S. J.; Patrikeeva, S. L.; Nanovskaya, T. N.; Hankins, G. D.; Ahmed, M. S. Opiates inhibit paclitaxel uptake by Pglycoprotein in preparations of human placental inside-out vesicles. Biochem. Pharmacol., 2009, 78(9), 1272-1278.
143. Han, Y.; Chin Tan, T. M.; Lim, L.Y. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol. Appl. Pharmacol., 2008, 230(3), 283-289.
144. Shukla, S.; Wu, C. P.; Nandigama, K.; Ambudkar, S. V. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol. Cancer Ther., 2007, 6(12 Pt 1), 3279-3286.
145. Tanaka, J.; Trianto, A.; Musman, M.; Issa, H. H.; Ohtani, I. I.; Ichiba, T.; Higa, T.; Yoshida, W. Y.; Scheuer, P.J. New polyoxygenated steroids exhibiting reversal of multidrug resistance from the gorgonian Isis hippuris. Tetrahedron, 2002, 58(32), 6259-6266.
146. Choi, C. H.; Kang, G.; Min, Y. D. Reversal of P-glycoproteinmediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med., 2003, 69(3), 235-240.
147. Wu, J. Y.; Fong, W. F.; Zhang, J. X.; Leung, C. H.; Kwong, H. L.; Yang, M. S.; Li, D.; Cheung, H.Y. Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani. Eur. J. Pharmacol., 2003, 473(1), 9-17.
148. Scambia, G.; Ranelletti, F. O.; Panici, P. B.; De Vincenzo, R.; Bonanno, G.; Ferrandina, G.; Piantelli, M.; Bussa, S.; Rumi, C.; Cianfriglia, M.; Mancuso, S. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 1994, 34(6), 459-464.
149. Limtrakul, P.; Khantamat, O.; Pintha, K. Inhibition of Pglycoprotein function and expression by kaempferol and quercetin. J. Chemother., 2005, 17(1), 86-95.
150. Ahmed-Belkacem, A.; Macalou, S.; Borrelli, F.; Capasso, R.; Fattorusso, E.; Taglialatela-Scafati, O.; Di Pietro, A. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J. Med. Chem., 2007, 50(8), 1933-1938.
151. Fong, W. F.; Wan, C. K.; Zhu, G.Y.; Chattopadhyay, A.; Dey, S.; Zhao, Z.; Shen, X. L. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med., 2007, 73(3), 212-220.
152. Munoz-Martinez, F.; Lu, P.; Cortes-Selva, F.; Perez-Victoria, J. M.; Jimenez, I. A.; Ravelo, A.G.; Sharom, F. J.; Gamarro, F.; Castanys, S. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res., 2004, 64(19), 7130-7138.
153. Choi, C. H.; Sun, K. H.; An, C. S.; Yoo, J. C.; Hahm, K. S.; Lee, I. H.; Sohng, J. K.; Kim, Y. C. Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin). Biochem. Biophys. Res. Commun., 2002, 295(4), 832-840.
154. Limtrakul, P.; Siwanon, S.; Yodkeeree, S.; Duangrat, C. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine, 2007, 14(6), 381-389.
155. Morita, H.; Koyama, K.; Sugimoto, Y.; Kobayashi, J. Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata. Bioorg. Med. Chem. Lett., 2005, 15(4), 1051-1054.
156. Brooks, T. A.; Kennedy, D. R.; Gruol, D. J.; Ojima, I.; Baer, M. R.; Bernacki, R. J. Structure-activity analysis of taxane-based broadspectrum multidrug resistance modulators. Anticancer Res., 2004, 24(2A), 409-415.
157. Zhao, X.; Gu, J.; Yin, D.; Chen, X. Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer. Bioorg. Med. Chem. Lett., 2004, 14(18), 4767-4770.
158. Yoshida, N.; Takada, T.; Yamamura, Y.; Adachi, I.; Suzuki, H.; Kawakami, J. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2-and breast cancer resistance proteinmediated transport. Drug Metab. Dispos., 2008, 36(7), 1206-1211.
159. Yoshida, N.; Koizumi, M.; Adachi, I.; Kawakami, J. Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. Food Chem. Toxicol., 2006, 44(12), 2033-2039.
160. Fu, L.; Liang, Y.; Deng, L.; Ding, Y.; Chen, L.; Ye, Y.; Yang, X.; Pan, Q. Characterization of tetrandrine, a potent inhibitor of Pglycoprotein-mediated multidrug resistance. Cancer Chemother. Pharmacol., 2004, 53(4), 349-356.
161. Woehlecke, H.; Osada, H.; Herrmann, A.; Lage, H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer, 2003, 107(5), 721-728.
162. Yu, S. T.; Chen, T. M.; Tseng, S.Y.; Chen, Y. H. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun., 2007, 358(1), 79-84.
163. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Kappl, R.; Huttermann, J.; Hyatt, J. A.; Edgar, K. J.; Schaefer, U. F.; Lehr, C. M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm., 2007, 4(3), 465-474.